Research progress of correlation between aldosterone and adipocytes

doi:10.3877/cma.j.issn.2095-9605.2023.03.011

Abstract

Abstract:

Aldosterone is a salt corticosteroid produced primarily by the globus pallidus of the adrenal cortex. Current studies have found a strong association between aldosterone and adipocytes. The effect of increased aldosterone, especially in patients with primary aldosteronism, on lipid metabolism and the relationship with obesity is still under investigation. This article reviews the research progress on the association between aldosterone and adipocytes and the correlation between patients with primary aldosteronism and obesity and other metabolic diseases.

Key words: Aldosterone, Primary aldosteronism, Obesity, Adipocytes

Wuyao Qin, Wenhui Gao, Hao Cui, Jiwen Shang. Research progress of correlation between aldosterone and adipocytes[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 209-214.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2023.03.011

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2023/V09/I03/209

Figures/Tables 2

References 59

[1]	Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China [J]. Lancet Diabetes Endocrinol, 2021, 9(6): 373-392.
[2]	Dinh Cat AN, Friederich-Persson M, White A, et al. aldosterone and obesity-related hypertension [J]. J Mol Endocrinol, 2016, 57(1): 7-21.
[3]	Vecchiola A, Lagos CF, Carvajal CA, et al. Aldosterone Production and Signaling Dysregulation in Obesity [J]. Curr Hypertens Rep, 2016, 18(3): 20.
[4]	李丽君, 侯小玲, 耿晓雯，等. 不同性别青年肥胖高血压患者醛固酮水平的变化 [J]. 中华高血压杂志, 2018, 26(01): 56-60.
[5]	Gorini S, Marzolla V, Mammi C, et al. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease [J]. Biomolecules, 2018, 8(3): 96.
[6]	Yuan Y, Xu X, Zhao C, et al. The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury [J]. Lab Invest, 2015, 95(12): 1374-1386.
[7]	Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline [J]. J Clin Endocrinol Metab, 2016, 101(5): 1889-1916.
[8]	Zhang Z, Luo Q, Tuersun T, et al. Higher prevalence of metabolic disorders in patients with bilateral primary aldosteronism than unilateral primary aldosteronism [J]. Clin Endocrinol (Oxf), 2021, 94(1): 3-11.
[9]	Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism [J]. Nat Rev Endocrinol, 2020, 16(10): 578-589.
[10]	Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis [J]. Circulation, 2015, 132(22): 2134-2145.
[11]	Janowska JD. C1q/TNF-related Protein 1, a Multifunctional Adipokine: An Overview of Current Data [J]. Am J Med Sci, 2020, 360(3): 222-228.
[12]	Infante M, Armani A, Marzolla V, et al. Adipocyte Mineralocorticoid Receptor [J]. Vitam Horm, 2019, 109: 189-209.
[13]	Kargi AY, Iacobellis G. Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications [J]. Int J Endocrinol, 2014, 2014: 614074.
[14]	Cannavo A, Bencivenga L, Liccardo D, et al. Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology [J]. Oxid Med Cell Longev, 2018, 2018: 1204598.
[15]	Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway [J]. Int J Obes (Lond), 2007, 31(5): 864-870.
[16]	Friedman J. 20 years of leptin: leptin at 20: an overview [J]. J Endocrinol, 2014, 223(1): T1-8.
[17]	Faulkner JL, Bruder-Nascimento T, Belin de Chantemèle EJ. The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease [J]. Curr Opin Nephrol Hypertens, 2018, 27(2): 63-69.
[18]	Huby AC, Otvos L Jr, Belin de Chantemèle EJ. Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice [J]. Hypertension, 2016, 67(5): 1020-1028.
[19]	Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases [J]. Biomed Res Int, 2014, 2014: 658913.
[20]	Shih PH, Shiue SJ, Chen CN, et al. Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis [J]. Mar Drugs, 2021, 19(3): 148.
[21]	刘华玲, 章小英, 叶建平. 肥胖相关脂肪因子与高血压的关系 [J]. 中华高血压杂志, 2019, 27(01): 25-29.
[22]	Wang Y, Li H, Yu XH, et al. CTRP1: A novel player in cardiovascular and metabolic diseases [J]. Cytokine, 2023, 164: 156162.
[23]	Xin Y, Lyu X, Wang C, Fu Y, Zhang S, Tian C, Li Q, Zhang D et al. Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients [J]. Endocr J, 2014, 61(9): 841-847.
[24]	Ren M, Pan J, Yu X, et al. CTRP1 prevents high fat diet-induced obesity and improves glucose homeostasis in obese and STZ-induced diabetic mice [J]. J Transl Med, 2022, 20(1): 449.
[25]	Han CY, Kang I, Harten IA, et al. Adipocyte-Derived Versican and Macrophage-Derived Biglycan Control Adipose Tissue Inflammation in Obesity [J]. Cell Rep, 2020, 31(13): 107818.
[26]	Reincke M, Bancos I, Mulatero P, et al. Diagnosis and treatment of primary aldosteronism [J]. Lancet Diabetes Endocrinol, 2021, 9(12): 876-892.
[27]	McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors [J]. Nat Med, 2012, 18(9): 1429-1433.
[28]	Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction [J]. Hypertension, 2012, 59(5): 1069-1078.
[29]	Urbanet R, Nguyen Dinh Cat A, Feraco A, et al. Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase [J]. Hypertension, 2015, 66(1): 149-157.
[30]	Hirata A, Maeda N, Nakatsuji H, et al. Contribution of glucocorticoid- mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction [J]. Biochem Biophys Res Commun, 2012, 419(2): 182-187.
[31]	Frigolet ME, Gutiérrez-Aguilar R. The colors of adipose tissue [J]. Gac Med Mex, 2020, 156(2): 142-149.
[32]	Marzolla V, Feraco A, Limana F, et al. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists [J]. J Endocrinol Invest, 2022, 45(1): 215-220.
[33]	Viengchareun S, Penfornis P, Zennaro MC, et al. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes [J]. Am J Physiol Endocrinol Metab, 2001, 280(4): E640-649.
[34]	Thuzar M, Law WP, Dimeski G, et al. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study [J]. Diabetes Obes Metab, 2019, 21(3): 509-516.
[35]	Fu M, Sun T, Bookout AL, et al. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis [J]. Mol Endocrinol, 2005, 19(10): 2437-2450.
[36]	Williams JS. Evolving research in nongenomic actions of aldosterone [J]. Curr Opin Endocrinol Diabetes Obes, 2013, 20(3): 198-203.
[37]	Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets [J]. Mol Cell Endocrinol, 2012, 350(2): 223-234.
[38]	Mihailidou AS, Tzakos AG, Ashton AW. Non-Genomic Effects of Aldosterone [J]. Vitam Horm, 2019, 109: 133-149.
[39]	Gorini S, Marzolla V, Mammi C, et al. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease [J]. Biomolecules, 2018, 8(3): 96.
[40]	Bełtowski J. Salt Intake, Aldosterone Secretion, and Obesity: Role in the Pathogenesis of Resistant Hypertension [J]. Am J Hypertens, 2021, 34(6): 588-590.
[41]	Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system [J]. Hypertension, 2005, 45(3): 356-362.
[42]	Rossi GP, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients [J]. J Clin Endocrinol Metab, 2008, 93(7): 2566-2571.
[43]	Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice [J]. J Am Coll Cardiol, 2017, 69(14): 1811-1820.
[44]	Chao CT, Wu VC, Kuo CC, et al. Diagnosis and management of primary aldosteronism: an updated review [J]. Ann Med, 2013, 45(4): 375-383.
[45]	Bu X, Sun F, Zhang H, et al. Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome [J]. J Diabetes Res, 2022, 2022: 8932133.
[46]	Rochlani Y, Pothineni NV, Kovelamudi S, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds [J]. Ther Adv Cardiovasc Dis, 2017, 11(8): 215-225.
[47]	张瑜, 王梦卉, 姚晓光, 等. 肥胖与非肥胖原发性醛固酮增多症患者的临床特点 [J]. 中华高血压杂志, 2015, 23(06): 571-573.
[48]	Zhang M, Hu T, Zhang S, et al. Associations of Different Adipose Tissue Depots with Insulin Resistance: A Systematic Review and Meta-analysis of Observational Studies [J]. Sci Rep, 2015, 5: 18495.
[49]	Chen S, Ma D, Su D, et al. The Optimal Axial Anatomical Site for a Single-Slice Area to Quantify the Total Volume of Visceral Adipose Tissue in Quantitative CT [J]. Front Endocrinol (Lausanne), 2022, 13: 870552.
[50]	Shibayama Y, Wada N, Baba S, et al. Relationship Between Visceral Fat and Plasma Aldosterone Concentration in Patients With Primary Aldosteronism [J]. J Endocr Soc, 2018, 2(11): 1236-1245.
[51]	Chen KM, Lee BC, Chen PT, et al. Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism [J]. Front Endocrinol (Lausanne), 2021, 12: 647184.
[52]	Wu C, Zhang H, Zhang J, et al. Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma [J]. Endocrinology, 2018, 159(1): 227-237.
[53]	Dankel SN, Svärd J, Matthä S, et al. COL6A3 expression in adipocytes associates with insulin resistance and depends on PPARγ and adipocyte size [J]. Obesity (Silver Spring), 2014, 22(8): 1807-1813.
[54]	Lenzini L, Rossitto G, Maiolino G, et al. A Meta-Analysis of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma [J]. J Clin Endocrinol Metab, 2015, 100(8): E1089-1095.
[55]	Zhang C, Wu L, Jiang L, et al. KCNJ5 Mutation Contributes to Complete Clinical Success in Aldosterone-Producing Adenoma: A Study From a Single Center [J]. Endocr Pract, 2021, 27(7): 736-742.
[56]	Chen KM, Chang YL, Wu TH, et al. Aldosterone-producing adenoma-harbouring KCNJ5 mutations is associated with lower prevalence of metabolic disorders and abdominal obesity [J]. J Hypertens, 2021, 39(12): 2353-2360.
[57]	van Rossum EF. Obesity and cortisol: New perspectives on an old theme [J]. Obesity (Silver Spring), 2017, 25(3): 500-501.
[58]	Er LK, Lin MC, Tsai YC, et al. Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma [J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001153.
[59]	Huang CY, Huang HL, Yang KC, et al. Serum Triglyceride Levels Independently Contribute to the Estimation of Visceral Fat Amount Among Nondiabetic Obese Adults [J]. Medicine (Baltimore), 2015, 94(23): e965.

Please choose a citation manager

Content to export